Literature DB >> 269447

Heterogeneity of nephritic factor and its identification as an immunoglobulin.

A E Davis, J B Ziegler, E W Gelfand, F S Rosen, C A Alper.   

Abstract

Complement C3 nephritic factor (NeF) produces alternative pathway-meciated C3 cleavage by binding to and stabilizing the alternative pathway C3 convertase, C3bBb. Some studies have suggested that NeF is an immunoglobulin, while others conclude that it is a distinct serum protein. The heterogeneity of NeF was evaluated by electrophoresis and isoelectric focusing of NeF-containing serum followed by hemolytic demonstration of NeF activity in agar gel. With each method, diffuse cathodal zones or multiple bands of hemolysis developed, which revealed remarkable variations in patterns from patient to patient. NeF activity was absorbed by and eluted from insolubilized antibody to Fc and Fab fragments of IgG. Immunoabsorption of six NeF-containing sera with insolubilized anti-kappa and anti-lambda light chain antisera revealed that NeF had kappa antigenic determinants in three, lambda antigenic determinants in one, and both kappa and lambda antigenic determinants in two. These data indicate that NeF is an oligoclonal immunoglobulin. Because NeF binds to the alternative pathway C3 convertase, C3bBb, we suggest that it is an antibody to a conformational antigen of the C3-factor B complex, and thereby stabilizes this complex.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 269447      PMCID: PMC431810          DOI: 10.1073/pnas.74.9.3980

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  ANTIGEN-ANTIBODY CROSSED ELECTROPHORESIS.

Authors:  C B LAURELL
Journal:  Anal Biochem       Date:  1965-02       Impact factor: 3.365

2.  THE BETA-1C GLOBULIN IN CHILDHOOD NEPHROTIC SYNDROME: LABORATORY DIAGNOSIS OF PROGRESSIVE GLOMERULONEPHRITIS.

Authors:  S P GOTOFF; F X FELLERS; G F VAWTER; C A JANEWAY; F S ROSEN
Journal:  N Engl J Med       Date:  1965-09-02       Impact factor: 91.245

3.  Disorders of the complement system in lipodystrophy.

Authors:  M M Ipp; J O Minta; E W Gelfand
Journal:  Clin Immunol Immunopathol       Date:  1977-03

4.  Transfer of C3 nephritic factor from mother to fetus. Is C3 nephritic factor IgG?

Authors:  A E Davis; M A Arnaout; C A Alper; F S Rosen
Journal:  N Engl J Med       Date:  1977-07-21       Impact factor: 91.245

5.  Homozygous deficiency of C3 in a patient with repeated infections.

Authors:  C A Alper; H R Colten; F S Rosen; A R Rabson; G M Macnab; J S Gear
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

6.  Isoelectric focusing in polyacrylamide gel and its application to immunoglobulins.

Authors:  Z L Awdeh; A R Williamson; B A Askonas
Journal:  Nature       Date:  1968-07-06       Impact factor: 49.962

7.  Nephritic factor: its structure and function and its relationship to initiating factor of the alternative pathway.

Authors:  R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

8.  Nephritic factor: Description of a new quantitative assay and findings in glomerulonephritis.

Authors:  W A Border; C B Wilson; O Götze
Journal:  Kidney Int       Date:  1976-10       Impact factor: 10.612

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.

Authors:  R D Schreiber; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

View more
  23 in total

1.  Identification of nephritic factor as an immunoglobulin.

Authors:  D G Williams; A Bartlett; P Duffus
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

2.  Requirements for the production of high-titre C3 nephritic factor (NEF) antibody in vitro.

Authors:  M A Marín; G Fontán; M López-Trascasa
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

3.  Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).

Authors:  Rachael Watson; Emma Wearmouth; Amy-Claire McLoughlin; Arthur Jackson; Sophie Ward; Paula Bertram; Karim Bennaceur; Catriona E Barker; Isabel Y Pappworth; David Kavanagh; Susan M Lea; John P Atkinson; Timothy H J Goodship; Kevin J Marchbank
Journal:  Mol Immunol       Date:  2014-08-21       Impact factor: 4.407

4.  Complement activation profiles in disease.

Authors:  D L Brown
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

Review 5.  Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Authors:  Marina Noris; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Pediatr Nephrol       Date:  2018-06-09       Impact factor: 3.714

6.  C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.

Authors:  Y C Ng; D K Peters
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

Review 7.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

8.  Molecular analysis of C3 allotypes in patients with nephritic factor.

Authors:  J E Finn; P W Mathieson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

9.  Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A Vanes; A Cats
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

10.  C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.

Authors:  A T Gewurz; S M Imherr; S Strauss; H Gewurz; C Mold
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.